United Therapeutics UTHR Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by United Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: United Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about United Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is United Therapeutics's investing cash flow?
- United Therapeutics (UTHR) reported investing cash flow of $743.7M in Q1 2026.
- How has United Therapeutics's investing cash flow changed year-over-year?
- United Therapeutics's investing cash flow increased by 551.5% year-over-year, from -$164.7M to $743.7M.
- What is the long-term trend for United Therapeutics's investing cash flow?
- Over 2 years (2021 to 2023), United Therapeutics's investing cash flow has grown at a 25.1% compound annual growth rate (CAGR), from -$486.9M to -$761.7M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.